Mitchell Ho
- Oncology top 1%
- CAR-T cell therapy research 49
- Immunology top 1%
- Toxin Mechanisms and Immunotoxins 28
- Immunotherapy and Immune Responses 12
- Biotechnology top 0.5%
- Transgenic Plants and Applications 10
- Hepatology top 2%
-
- Monoclonal and Polyclonal Antibodies Research 58
-
- Glycosylation and Glycoproteins Research 29
-
- Occupational and environmental lung diseases 16
-
- Proteoglycans and glycosaminoglycans research 11
- Co-authors
- Ira PastanRaffit HassanWei GaoHeungnam KimMingqian FengYu‐suke TorisawaShuichi TakayamaAmy Y. Hsiao
- Cited by
- OncologyImmunologyBiotechnology
- Journals
- Proceedings of the National Academy of Sciences (8 papers)Clinical Cancer Research (7 papers)Cancer Research (7 papers)
- Partner nations
- United StatesChinaUnited Kingdom
In The Last Decade
Mitchell Ho
133 papers receiving 6.4k citations
Hit Papers
Peers
Comparison fields: 5 of 126
- Oncology 2.1k
- Immunology 1.7k
- Biotechnology 668
- Hepatology 518
- Radiology, Nuclear Medicine and Imaging 1.4k
Countries citing papers authored by Mitchell Ho
This map shows the geographic impact of Mitchell Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell Ho more than expected).
Fields of papers citing papers by Mitchell Ho
This network shows the impact of papers produced by Mitchell Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell Ho. The network helps show where Mitchell Ho may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mitchell Ho, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2026 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 0 | |
| 5 | 2024 | 14 | |
| 6 | 2023 | 23 | |
| 7 | 2023 | 13 | |
| 8 | 2022 | 27 | |
| 9 | 2022 | 8 | |
| 10 | 2022 | 31 | |
| 11 | 2020 | 41 | |
| 12 | 2019 | 9 | |
| 13 | Development of CAR T cell therapy targeting glypican-3 in liver cancer | 2018 | 1 |
| 14 | 2017 | 44 | |
| 15 | 2016 | 48 | |
| 16 | 2013 | 38 | |
| 17 | 2011 | 12 | |
| 18 | 2010 | 34 | |
| 19 | 2010 | 18 | |
| 20 | 2007 | 86 |
About Mitchell Ho
Mitchell Ho is a scholar working on Biotechnology, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 142 papers that have together received 6.5k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (58 papers), CAR-T cell therapy research (49 papers), Glycosylation and Glycoproteins Research (29 papers), Toxin Mechanisms and Immunotoxins (28 papers), Occupational and environmental lung diseases (16 papers), Immunotherapy and Immune Responses (12 papers), Proteoglycans and glycosaminoglycans research (11 papers) and Transgenic Plants and Applications (10 papers). The work is most often cited by research in Oncology (2.1k citations), Immunology (1.7k citations) and Biotechnology (668 citations). Mitchell Ho has collaborated with scholars based in United States, China and United Kingdom. Frequent co-authors include Ira Pastan, Raffit Hassan, Wei Gao, Heungnam Kim, Mingqian Feng, Yu‐suke Torisawa, Shuichi Takayama, Amy Y. Hsiao, Steven G. Allen and Yi‐Chung Tung. Their work appears in journals such as Proceedings of the National Academy of Sciences, Clinical Cancer Research, Cancer Research, Scientific Reports and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.